AstraZeneca/Infinity’s Hsp90 Inhibitor Fails Phase II Prostate Cancer Study
This article was originally published in The Pink Sheet Daily
Phase III study of IPI-504 in gastrointestinal cancer still on track for later this year.
You may also be interested in...
Positive PFS data in patients treated with retaspimycin presented at ASCO; Phase III to start in third quarter.
BMS gains several clinical-stage oncology programs with agreement to acquire Kosan for $190 million.
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.